XIENCE Alpine, XIENCE Sierra, XIENCE PRO S, and XIENCE Skypoint Everolimus Eluting Coronary Stent Systems
Abbott Vascular · Decision date May 22, 2026
What did the FDA decide?
FDA records P110019/S141 as a supplement to PMA P110019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 22, 2026.
FDA approval order statement
reduced confirmatory testing of Everolimus BHT reference standard
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- May 22, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P110019/S141
- Regulatory pathway
- PMA supplement
- Applicant
- Abbott Vascular
- Product code
- NIQ
- Decision code
- OK30
- Decision date
- May 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Coronary drug-eluting stent.
- Applicant
- Abbott Vascular
- Product code
- NIQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P110019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P110019 · Original PMA
Xience Skypoint Everolimus Eluting Coronary Stent System
P110019/S136 · Related supplement
XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine); XIENCE Sierra Everolimus Eluting Coronary Sten
P110019/S137 · Related supplement
XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine OTW)
P110019/S138 · Related supplement
XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine), XIENCE Sierra Everolimus Eluting Coronary Stent
P110019/S139 · Related supplement
XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine); XIENCE Sierra Everolimus Eluting Coronary Stent
P110019/S140 · Related supplement
XIENCE Alpine Everolimus Eluting Coronary Stent System; XIENCE Sierra Everolimus Eluting Coronary Stent System; XIENCE P
P110019/S141 received
Application receipt date recorded by FDA.
P110019/S141 · FDA decision
30-Day Notice
P110019/S142 · Related supplement
XIENCE Alpine; XIENCE Sierra; XIENCE PROs; XIENCE Skypoint Everolimus Eluting Coronary Stent Systems
P110019/S144 · Related supplement
XIENCE PROS Everolimus Eluting Coronary Stent System (XIENCE PRO5); XIENCE Skypoint Everolimus Eluting Coronary Stent Sy
P110019/S145 · Related supplement
XIENCE PRO5 Everolimus Eluting Coronary Stent System (XIENCE PRO5), XIENCE Skypoint Everolimus Eluting Coronary Stent Sy
Timeline entries are records held by MedtechLedger for P110019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular | PMA approval | Nov 1, 2011 | FDA | |
| Abbott Vascular | PMA supplement | Aug 16, 2025 | FDA | |
| Abbott Vascular | PMA supplement | Oct 22, 2025 | FDA | |
| Abbott Vascular | PMA supplement | Feb 3, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Feb 5, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Feb 13, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Jul 31, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Aug 28, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Oct 1, 2026 | FDA |
Explore the linked device profile
Other records with product code NIQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA supplement | Oct 16, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S066 | Biotronik AG | PMA supplement | Sep 24, 2026 | FDA |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 21, 2026 | FDA | |
| Medtronic Vascular | PMA supplement | Aug 14, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S065 | Biotronik AG | PMA supplement | Aug 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Vascular
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3200 Lakeside Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P110019/S141
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





